Recombinate 1000 IU, powder and solvent for solution for injection

국가: 아일랜드

언어: 영어

출처: HPRA (Health Products Regulatory Authority)

유효 성분:

Factor viii, human recombinant

제공처:

Baxalta Innovations GmbH

ATC 코드:

B02BD; B02BD02

INN (국제 이름):

Factor viii, human recombinant

복용량:

1000 IU international unit(s)

약제 형태:

Powder and solvent for solution for injection

관리 경로:

administered intravenously

패키지 단위:

Pack size of 1

처방전 유형:

Product subject to prescription which may not be renewed (A)

치료 그룹:

antihaemorrhagics: blood coagulation factor VIII

치료 영역:

Blood coagulation factors; coagulation factor VIII

치료 징후:

Treatment and prophylaxis of bleeding in patients with Haemophilia A (congenital Factor VIII deficiency). This product does not contain von Willebrand factor and is therefore not indicated in von Willebrand’s disease

승인 상태:

Not marketed

승인 날짜:

1993-10-26

환자 정보 전단

Package leaflet: Information for the user
Recombinate 250 IU/10 ml powder and solvent for solution for
injection.
Recombinate 500 IU/10 ml powder and solvent for solution for
injection.
Recombinate 1000 IU/10 ml powder and solvent for solution for
injection.
Octocog alfa (recombinant coagulation factor VIII)
Read all of this leaflet carefully before you start using this
medicine because it contains important
information for you.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, or pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects talk to your doctor, or pharmacist or
nurse. This includes any possible
side effects not listed in this leaflet.
What is in this leaflet
1.
What Recombinate is and what it is used for
2.
What you need to know before you use Recombinate
3.
How to use Recombinate
4.
Possible side effects
5.
How to store Recombinate
6.
Contents of the pack and other information
1.
What Recombinate is and what it is used for
Recombinate belongs to a pharmacotherapeutic group called blood
coagulation factor VIII.
Recombinate is used in patients with haemophilia A (congenital factor
VIII deficiency) for

prevention of bleeding

treatment of bleeding (e.g. muscle bleeding, oral bleeding, bleeding
at the site of surgery).
The product does not contain von Willebrand factor and is therefore
not to be used in von Willebrand’s
disease (a special blood coagulation disorder).
2.
What you need to know before you use Recombinate
Do not use Recombinate

If you are allergic to octocog alfa, to mouse, bovine or hamster
proteins or to any of the other
ingredients of this medicine (listed in section 6).
If you are unsure about this, ask your doctor.
Warnings and precautions
When allergic reactions occur:

There is a rare chance that you may experience an anaphylactic
reaction (a severe, sudden allergic
reac

제품 특성 요약

Health Products Regulatory Authority
18 November 2020
CRN00C1DY
Page 1 of 10
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Recombinate 1000 IU, powder and solvent for solution for injection
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Octocog alfa 100 IU per ml of reconstituted solution
After reconstitution: One vial of 10 ml contains 1000 IU octocog alfa
Recombinate 1000 IU, contains nominally 1000 IU octocog alfa,
recombinant, coagulation factor VIII per vial.
The product contains approximately 100 IU/ml octocog alfa, recombinant
coagulation factor VIII when reconstituted with 10 ml
of sterile water for injections.
The potency is determined using the European Pharmacopoeia chromogenic
assay against the FDA Mega Standard calibrated
to the WHO Standard. The specific activity of Recombinate is
approximately 4000 - 8000 IU/mg protein.
Recombinate contains recombinant coagulation factor VIII (INN: octocog
alfa). Octocog alfa (recombinant coagulation factor
VIII) is a purified protein consisting of 2332 amino acids. It has an
amino acid sequence that is comparable to factor VIII, and
post-translational modifications that are similar to the plasma
derived molecule. Recombinant coagulation factor VIII is a
glycoprotein that is expressed by genetically engineered mammalian
cells derived from a Chinese Hamster Ovary cell line.
Excipients with known effect: sodium
For the full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Powder and solvent for solution for injection.
White to off-white friable powder. The solvent (sterilised water for
injections) is a clear and colourless liquid.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Treatment and prophylaxis of bleeding in patients with Haemophilia A
(congenital Factor VIII deficiency).
This product does not contain von Willebrand factor and is therefore
not indicated in von Willebrand’s disease.
Recombinate is indicated for all age groups from neonates to adults.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
4.2.1 POSOLOGY
The dosage and durati